Dr Ben Kong

Dr Ben Kong

Senior Research Fellow

BSc (Hons I), MBBS (USyd), Grad Cert Drug Development (UNSW), PhD (Usyd), FRACP

Medicine & Health
School of Clinical Medicine

Dr Ben Kong is a Senior Research Fellow in Poor Outcomes Cancers within SPHERE Cancer Clinical Academic Group. He is appointed as a Medical Oncologist at Prince of Wales Hospital where he treats patients with lung and head and neck cancers. He is also a Research Fellow at the NHMRC Clinical Trials Centre where he is responsible for the design and conduct of investigator-initiated cancer clinical trials with the Co-operative Group for Neuro-Oncology (COGNO). 

Prior to joining SPHERE, he completed his PhD in Cancer Immunology within the Dendritic Cell Research Group at the ANZAC Research Institute with Professor Derek Hart, characterising circulating dendritic cells in patients with glioblastoma and developing pre-clinical studies examining combination immune checkpoint inhibitors with dendritic cell vaccination using CMV as a model tumour antigen. He is currently leading clinical research in lung cancer and brain metastases with the aim of extending this into translational research in cancers affecting the central nervous system to develop more effective treatments in brain cancer. 


Ben is a member of the UNSW Australian Centre for NanoMedicine and a mentor with UNSW Founders Health10x and Biotech Accelerator Programmes.

 

 

Phone
+61 2 9382 5111
Location
Level 4, Lowy Cancer Research Centre
  • Journal articles | 2025
    McParland K; Koh ES; Kong B; Sim HW; Thavaneswaran S; Yip S; Barnes EH; Ballinger ML; Thomas DM; De Abreu Lourenco R; Simes J; Sebastian L; Wheeler PJ; Spyridopoulos D; Hawkins C; Pitz M; O'Callaghan C; Gan HK, 2025, 'Low & Anaplastic Grade Glioma Umbrella Study of MOlecular Guided TherapieS (LUMOS-2): study protocol for a phase 2, prospective, multicentre, open-label, multiarm, biomarker-directed, signal-seeking, umbrella, clinical trial for recurrent IDH mutant, grade 2/3 glioma', BMJ Open, 15, pp. e087922, http://dx.doi.org/10.1136/bmjopen-2024-087922
    Journal articles | 2025
    Shahnam A; Davis A; Brown LJ; Sullivan I; Lin K; Ng C; Yeo N; Kong BY; Khoo T; Warburton L; Da Silva IP; Mullally W; Xu W; O'Byrne K; Bray V; Pal A; Mersaides A; Itchins M; Arulananda S; Nagrial A; Kao S; Alexander M; Lee CK; Solomon B; John T, 2025, 'Real-World outcomes of Non-Small cell lung cancer patients harbouring KRAS G12C and KRAS G12D mutations', Lung Cancer, 201, http://dx.doi.org/10.1016/j.lungcan.2025.108421
    Journal articles | 2025
    Yeo N; Johnston F; Fay L; Lilburn P; Kennedy D; Barrett H; Shand A; Kidson-Gerber G; Tang M; Challis D; Kong BY, 2025, 'Beating the Odds: A Successful Pregnancy in a Patient With ALK-Rearranged Lung Cancer on Alectinib', Case Reports in Medicine, 2025, http://dx.doi.org/10.1155/carm/9032427
    Journal articles | 2025
    Yuile A; Satgunaseelan L; Alexander KL; Thavaneswaran S; Sim HW; Krasovitsky M; Kong BY; Miller S; Buckland ME; Lee M; Wei G; Kastelan M; Wong M; Wilson I; Bayly A; Varikatt W; Lwin Z; Turner C; Back MF; Pavlakis N; Wei JQ; Hudson A; Chan DL; Wheeler HR; Lee A, 2025, 'Clinical outcomes and management of CDKN2A/B homozygously deleted IDH-mutant astrocytomas—a cohort study and patterns of care survey', Neuro Oncology Practice, 12, pp. 787 - 796, http://dx.doi.org/10.1093/nop/npaf045
    Journal articles | 2024
    Alexander M; Rogers J; Parakh S; Mitchell P; Clay TD; Kao S; Hughes BGM; Itchins M; Kong BY; Pavlakis N; Solomon BJ; John T, 2024, 'Lurbinectedin in small cell lung cancer: real-world experience of a multicentre national early access programme', Internal Medicine Journal, 54, pp. 1087 - 1096, http://dx.doi.org/10.1111/imj.16348
    Journal articles | 2024
    Brown LJ; Khou V; Brown C; Alexander M; Jayamanne D; Wei J; Gray L; Chan WY; Smith S; Harden S; Mersiades A; Warburton L; Itchins M; Lee JH; Pavlakis N; Clarke SJ; Boyer M; Nagrial A; Hau E; Pires da Silva I; Kao S; Kong BY, 2024, 'First-line chemoimmunotherapy and immunotherapy in patients with non-small cell lung cancer and brain metastases: a registry study', Frontiers in Oncology, 14, http://dx.doi.org/10.3389/fonc.2024.1305720
    Journal articles | 2023
    Agar MR; Nowak AK; Hovey EJ; Barnes EH; Simes J; Vardy JL; Wheeler HR; Kong BY; Leonard R; Hall M; Tim E; Spyridopoulos D; Sim HW; Lwin Z; Dowling A; Harrup R; Jennens R; Kichenadasse G; Dunlop T; Gzell C; Koh ES, 2023, 'Acetazolamide versus placebo for cerebral oedema requiring dexamethasone in recurrent and/or progressive high-grade glioma: phase II randomised placebo-controlled double-blind study', BMJ Supportive and Palliative Care, 13, pp. 354 - 362, http://dx.doi.org/10.1136/spcare-2022-004119
    Journal articles | 2023
    Sim H-W; Wachsmuth L; Barnes EH; Yip S; Koh E-S; Hall M; Jennens R; Ashley DM; Verhaak RG; Heimberger AB; Rosenthal MA; Hovey EJ; Ellingson BM; Tognela A; Gan HK; Wheeler H; Back M; McDonald KL; Long A; Cuff K; Begbie S; Gedye C; Mislang A; Le H; Johnson MO; Kong BY; Simes JR; Lwin Z; Khasraw M, 2023, 'NUTMEG: A randomized phase II study of nivolumab and temozolomide versus temozolomide alone in newly diagnosed older patients with glioblastoma.', Neurooncol Adv, 5, pp. vdad124, http://dx.doi.org/10.1093/noajnl/vdad124
    Journal articles | 2023
    Trinder SM; McKay C; Power P; Topp M; Chan B; Valvi S; McCowage G; Govender D; Kirby M; Ziegler DS; Manoharan N; Hassall T; Kellie S; Heath J; Alvaro F; Wood P; Laughton S; Tsui K; Dodgshun A; Eisenstat DD; Endersby R; Luen SJ; Koh ES; Sim HW; Kong B; Gottardo NG; Whittle JR; Khuong-Quang DA; Hansford JR, 2023, 'BRAF-mediated brain tumors in adults and children: A review and the Australian and New Zealand experience', Frontiers in Oncology, 13, http://dx.doi.org/10.3389/fonc.2023.1154246
    Journal articles | 2023
    Wei JQ; Yuile A; Itchins M; Kong BY; Li BT; Pavlakis N; Chan DL; Clarke SJ, 2023, 'Anti-PD-1 Monoclonal Antibodies (mAbs) Are Superior to Anti-PD-L1 mAbs When Combined with Chemotherapy in First-Line Treatment for Metastatic Non-Small Cell Lung Cancer (mNSCLC): A Network Meta-Analysis', Biomedicines, 11, http://dx.doi.org/10.3390/biomedicines11071827
    Journal articles | 2022
    Halkett GKB; Breen LJ; Berg M; Sampson R; Sim HW; Gan HK; Kong BY; Nowak AK; Day BW; Harrup R; James M; Saran F; Mcfarlane B; Tse C; Koh ES, 2022, 'Determining the Research Priorities for Adult Primary Brain Tumours in Australia and New Zealand: A Delphi Study with Consumers, Health Professionals, and Researchers', Current Oncology, 29, pp. 9928 - 9955, http://dx.doi.org/10.3390/curroncol29120781
    Journal articles | 2022
    Kong BY; Carter C; Nowak AK; Hovey E; Lwin Z; Haghighi N; Gan HK; Sim HW; Ziegler DS; Barton K; Parkinson J; Leonard R; Khasraw M; Foote M, 2022, 'Barriers and potential solutions to international collaboration in neuro-oncology clinical trials: Challenges from the Australian perspective', Asia Pacific Journal of Clinical Oncology, 18, pp. 259 - 266, http://dx.doi.org/10.1111/ajco.13606
    Journal articles | 2022
    Kong BY; Sim HW; Barnes EH; Nowak AK; Hovey EJ; Jeffree R; Harrup R; Parkinson J; Gan HK; Pinkham MB; Yip S; Hall M; Tu E; Carter C; Koh ES; Lwin Z; Dowling A; Simes JS; Gedye C, 2022, 'Multi-Arm GlioblastoMa Australasia (MAGMA): Protocol for a multiarm randomised clinical trial for people affected by glioblastoma', BMJ Open, 12, http://dx.doi.org/10.1136/bmjopen-2021-058107
    Journal articles | 2021
    Kong B; Sim H-W; Amanuel B; Day B; Buckland M; Verhaak R; Yip S; Johns T; Lwin Z; Rosenthal M; Nowak AK; Barnes EH; Scott AM; Parkinson J; Jeffree R; Lourenco RDA; Lau P; Whittle J; Hovey E; Cher L; Kichendasse G; Hall M; Robinson C; Thomas M; Giardina T; Tu E; Khasraw M; Koh E-S; Gan H, 2021, 'INNV-08. LOW AND INTERMEDIATE GRADE GLIOMA UMBRELLA STUDY OF MOLECULAR GUIDED THERAPIES (LUMOS) STUDY', Neuro-Oncology, 23, pp. vi106 - vi107, http://dx.doi.org/10.1093/neuonc/noab196.420
    Journal articles | 2021
    Kong B; Sim H-W; Koh E-S; Gan H; Barnes EH; Yip S; Nowak AK; Lau P; Cuff K; Khoo E; Lwin Z; Cooper A; Dowling A; Linton A; Harrup R; Dunlop T; Hovey E; Parkinson J; Jeffree R; Hall M; Tu E; Andrew D; Simes J; Gedye C, 2021, 'RTID-05. THE MULTI-ARM GLIOBLASTOMA AUSTRALASIA (MAGMA) TRIAL', Neuro-Oncology, 23, pp. vi193 - vi194, http://dx.doi.org/10.1093/neuonc/noab196.767
    Journal articles | 2021
    Kong BY; Sim HW; Nowak AK; Yip S; Barnes EH; Day BW; Buckland ME; Verhaak R; Johns T; Robinson C; Thomas MA; Giardina T; Lwin Z; Scott AM; Parkinson J; Jeffree R; Lourenco RDA; Hovey EJ; Cher LM; Kichendasse G; Khasraw M; Hall M; Tu E; Amanuel B; Koh ES; Gan HK, 2021, 'LUMOS - Low and Intermediate Grade Glioma Umbrella Study of Molecular Guided TherapieS at relapse: Protocol for a pilot study', BMJ Open, 11, http://dx.doi.org/10.1136/bmjopen-2021-054075
    Journal articles | 2021
    Oh B; Boyle F; Pavlakis N; Clarke S; Eade T; Hruby G; Lamoury G; Carroll S; Morgia M; Kneebone A; Stevens M; Liu W; Corless B; Molloy M; Kong B; Libermann T; Rosenthal D; Back M, 2021, 'The gut microbiome and cancer immunotherapy: Can we use the gut microbiome as a predictive biomarker for clinical response in cancer immunotherapy?', Cancers, 13, http://dx.doi.org/10.3390/cancers13194824
    Journal articles | 2020
    Fromm PD; Silveira PA; Hsu JL; Papadimitrious MS; Lo TH; Ju X; Kupresanin F; Romano A; Hsu WH; Bryant CE; Kong B; Abadir E; Mekkawy A; M. McGuire H; Groth BFDS; Cunningham I; Newman E; Gibson J; Hogarth PM; Hart DNJ; Clark GJ, 2020, 'Distinguishing human peripheral blood CD16+ myeloid cells based on phenotypic characteristics', Journal of Leukocyte Biology, 107, pp. 323 - 339, http://dx.doi.org/10.1002/JLB.5A1119-362RRR
    Journal articles | 2019
    Bryant CE; Sutherland S; Kong B; Papadimitrious MS; Fromm PD; Hart DNJ, 2019, 'Dendritic cells as cancer therapeutics', Seminars in Cell and Developmental Biology, 86, pp. 77 - 88, http://dx.doi.org/10.1016/j.semcdb.2018.02.015
    Journal articles | 2019
    Kong BY; Bolton H; Kim JW; Silveira PA; Fromm PD; Clark GJ, 2019, 'On the other side: Manipulating the immune checkpoint landscape of dendritic cells to enhance cancer immunotherapy', Frontiers in Oncology, 9, http://dx.doi.org/10.3389/fonc.2019.00050
    Journal articles | 2018
    Eroglu Z; Zaretsky JM; Hu-Lieskovan S; Kim DW; Algazi A; Johnson DB; Liniker E; Kong B; Munhoz R; Rapisuwon S; Gherardini PF; Chmielowski B; Wang X; Shintaku IP; Wei C; Sosman JA; Joseph RW; Postow MA; Carlino MS; Hwu WJ; Scolyer RA; Messina J; Cochran AJ; Long GV; Ribas A, 2018, 'High response rate to PD-1 blockade in desmoplastic melanomas', Nature, 553, pp. 347 - 350, http://dx.doi.org/10.1038/nature25187
    Journal articles | 2018
    Hsu JL; Bryant CE; Papadimitrious MS; Kong B; Gasiorowski RE; Orellana D; McGuire HM; Groth BFDS; Joshua DE; Ho PJ; Larsen S; Iland HJ; Gibson J; Clark GJ; Fromm PD; Hart DNJ, 2018, 'A blood dendritic cell vaccine for acute myeloid leukemia expands anti-tumor T cell responses at remission', Oncoimmunology, 7, http://dx.doi.org/10.1080/2162402X.2017.1419114
    Journal articles | 2017
    Bowyer S; Prithviraj P; Lorigan P; Larkin J; McArthur G; Atkinson V; Millward M; Khou M; Diem S; Ramanujam S; Kong B; Liniker E; Guminski A; Parente P; Andrews MC; Parakh S; Cebon J; Long GV; Carlino MS; Klein O, 2017, 'Reply to 'Comment on 'Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy''', British Journal of Cancer, 116, pp. e15, http://dx.doi.org/10.1038/bjc.2017.59
    Journal articles | 2017
    Hwang SJE; Kong BY; Chou S; Wakade D; Carlino MS; Fernandez-Penas P, 2017, 'Acute Truncal Lymphedema Secondary to Axillary Metastatic Melanoma Presenting Like Cellulitis', Case Reports in Medicine, 2017, http://dx.doi.org/10.1155/2017/5462929
    Journal articles | 2017
    Long GV; Atkinson V; Cebon JS; Jameson MB; Fitzharris BM; McNeil CM; Hill AG; Ribas A; Atkins MB; Thompson JA; Hwu WJ; Hodi FS; Menzies AM; Guminski AD; Kefford R; Kong BY; Tamjid B; Srivastava A; Lomax AJ; Islam M; Shu X; Ebbinghaus S; Ibrahim N; Carlino MS, 2017, 'Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial', Lancet Oncology, 18, pp. 1202 - 1210, http://dx.doi.org/10.1016/S1470-2045(17)30428-X
    Journal articles | 2017
    Naidoo J; Wang X; Woo KM; Iyriboz T; Halpenny D; Cunningham J; Chaft JE; Segal NH; Callahan MK; Lesokhin AM; Rosenberg J; Voss MH; Rudin CM; Rizvi H; Hou X; Rodriguez K; Albano M; Gordon RA; Leduc C; Rekhtman N; Harris B; Menzies AM; Guminski AD; Carlino MS; Kong BY; Wolchok JD; Postow MA; Long GV; Hellmann MD, 2017, 'Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy', Journal of Clinical Oncology, 35, pp. 709 - 717, http://dx.doi.org/10.1200/JCO.2016.68.2005
    Journal articles | 2017
    Vilain RE; Menzies AM; Wilmott JS; Kakavand H; Madore J; Guminski A; Liniker E; Kong BY; Cooper AJ; Howle JR; Saw RPM; Jakrot V; Lo S; Thompson JF; Carlino MS; Kefford RF; Long GV; Scolyer RA, 2017, 'Dynamic changes in PD-L1 expression and immune infiltrates early during treatment predict response to PD-1 blockade in Melanoma', Clinical Cancer Research, 23, pp. 5024 - 5033, http://dx.doi.org/10.1158/1078-0432.CCR-16-0698
    Journal articles | 2016
    Bowyer S; Prithviraj P; Lorigan P; Larkin J; McArthur G; Atkinson V; Millward M; Khou M; Diem S; Ramanujam S; Kong B; Liniker E; Guminski A; Parente P; Andrews MC; Parakh S; Cebon J; Long GV; Carlino MS; Klein O, 2016, 'Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy', British Journal of Cancer, 114, pp. 1084 - 1089, http://dx.doi.org/10.1038/bjc.2016.107
    Journal articles | 2016
    Hwang SJE; Carlos G; Wakade D; Byth K; Kong BY; Chou S; Carlino MS; Kefford R; Fernandez-Penas P, 2016, 'Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohort', Journal of the American Academy of Dermatology, 74, pp. 455 - 461.e1, http://dx.doi.org/10.1016/j.jaad.2015.10.029
    Journal articles | 2016
    Kong BY; Carlino MS; Menzies AM, 2016, 'Biology and treatment of BRAF mutant metastatic melanoma', MELANOMA MANAGEMENT, 3, pp. 33 - 45, http://dx.doi.org/10.2217/mmt.15.38
    Journal articles | 2016
    Kong BY; Menzies AM; Saunders CAB; Liniker E; Ramanujam S; Guminski A; Kefford RF; Long GV; Carlino MS, 2016, 'Residual FDG-PET metabolic activity in metastatic melanoma patients with prolonged response to anti-PD-1 therapy', Pigment Cell and Melanoma Research, 29, pp. 572 - 577, http://dx.doi.org/10.1111/pcmr.12503
    Journal articles | 2016
    Kong BY; Micklethwaite KP; Swaminathan S; Kefford RF; Carlino MS, 2016, 'Autoimmune hemolytic anemia induced by anti-PD-1 therapy in metastatic melanoma', Melanoma Research, 26, pp. 202 - 204, http://dx.doi.org/10.1097/CMR.0000000000000232
    Journal articles | 2016
    Liniker E; Menzies AM; Kong BY; Cooper A; Ramanujam S; Lo S; Kefford RF; Fogarty GB; Guminski A; Wang TW; Carlino MS; Hong A; Long GV, 2016, 'Activity and safety of radiotherapy with anti-PD-1 drug therapy in patients with metastatic melanoma', Oncoimmunology, 5, http://dx.doi.org/10.1080/2162402X.2016.1214788
    Journal articles | 2015
    Liniker E; Kong B; Menzies AM; Cooper A; Ramanujam S; Lo S; Kefford RF; Fogarty GB; Guminski A; Wang TW; Carlino MS; Hong A; Long GV, 2015, 'Safety and Activity of Combined Radiotherapy (RT) and Anti-PD-1 Antibodies (PD-1) in Patients (pts) with Metastatic Melanoma', EUROPEAN JOURNAL OF CANCER, 51, pp. S664 - S664, http://dx.doi.org/10.1016/S0959-8049(16)31821-4
    Journal articles | 2015
    Liniker E; Kong B; Menzies AM; Cooper AJ; Kefford RF; Fogarty GB; Guminski A; Carlino MS; Wang TW; Long GV; Hong A, 2015, 'Safety and Activity of Combined Radiation Therapy (RT) and Anti-PD-1 Antibodies (PD-1) in Patients (pts) With Metastatic Melanoma', INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 93, pp. E635 - E635, http://dx.doi.org/10.1016/j.ijrobp.2015.07.2168
    Journal articles | 2007
    Clarke RJ; Apell HJ; Kong BY, 2007, 'Allosteric effect of ATP on Na+,K+-ATPase Conformational kinetics', Biochemistry, 46, pp. 7034 - 7044, http://dx.doi.org/10.1021/bi700619s
    Journal articles | 2004
    Buhagiar KA; Hansen PS; Kong BY; Clarke RJ; Fernandes C; Rasmussen HH, 2004, 'Dietary cholesterol alters Na+/K+ selectivity at intracellular Na+/K+ pump sites in cardiac myocytes', American Journal of Physiology Cell Physiology, 286, pp. C398 - C405, http://dx.doi.org/10.1152/ajpcell.00016.2003
    Journal articles | 2004
    Kong BY; Clarke RJ, 2004, 'Identification of Potential Regulatory Sites of the Na+,K +-ATPase by Kinetic Analysis', Biochemistry, 43, pp. 2241 - 2250, http://dx.doi.org/10.1021/bi0355443
    Journal articles | 2002
    Hansen PS; Buhagiar KA; Kong BY; Clarke RJ; Gray DF; Rasmussen HH, 2002, 'Dependence of Na+-K+ pump current-voltage relationship on intracellular Na+, K+, and Cs+ in rabbit cardiac myocytes', American Journal of Physiology Cell Physiology, 283, pp. C1511 - C1521, http://dx.doi.org/10.1152/ajpcell.01343.2000
  • Conference Papers | 2023
    Sim HW; Wachsmuth L; Barnes EH; Yip S; Koh ES; Hall M; Jennens R; Ashley DM; Verhaak RG; Heimberger AB; Rosenthal MA; Hovey EJ; Ellingson BM; Tognela A; Gan HK; Wheeler H; Back M; Mcdonald KL; Long A; Cuff K; Begbie S; Gedye C; Mislang A; Le H; Johnson MO; Kong BY; Simes JR; Lwin Z; Khasraw M, 2023, 'NUTMEG: A randomized phase II study of nivolumab and temozolomide versus temozolomide alone in newly diagnosed older patients with glioblastoma', in Neuro Oncology Advances, http://dx.doi.org/10.1093/noajnl/vdad124
    Conference Papers | 2021
    Kong B; Sim H-W; Amanuel B; Day B; Buckland M; Verhaak R; Yip S; Johns T; Lwin Z; Rosenthal M; Nowak AK; Barnes EH; Scott AM; Parkinson J; Jeffree R; Lourenco RDA; Lau P; Whittle J; Hovey E; Cher L; Kichendasse G; Hall M; Robinson C; Thomas M; Giardina T; Tu E; Khasraw M; Koh E-S; Gan H, 2021, 'LOW AND INTERMEDIATE GRADE GLIOMA UMBRELLA STUDY OF MOLECULAR GUIDED THERAPIES (LUMOS) STUDY', in NEURO-ONCOLOGY, OXFORD UNIV PRESS INC, MA, Boston, pp. 106 - 106, presented at 26th Annual Scientific Meeting and Education Day of the Society-for-Neuro-Oncology (SNO), MA, Boston, 18 November 2021 - 21 November 2021, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000757356200422&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Papers | 2021
    Kong B; Sim H-W; Koh E-S; Gan H; Barnes EH; Yip S; Nowak AK; Lau P; Cuff K; Khoo E; Lwin Z; Cooper A; Dowling A; Linton A; Harrup R; Dunlop T; Hovey E; Parkinson J; Jeffree R; Hall M; Tu E; Andrew D; Simes J; Gedye C, 2021, 'THE MULTI-ARM GLIOBLASTOMA AUSTRALASIA (MAGMA) TRIAL', in NEURO-ONCOLOGY, OXFORD UNIV PRESS INC, MA, Boston, pp. 193 - 194, presented at 26th Annual Scientific Meeting and Education Day of the Society-for-Neuro-Oncology (SNO), MA, Boston, 18 November 2021 - 21 November 2021
    Conference Papers | 2019
    Sutherland S; Abadir E; Kong B; Stockler M; Mahon K; Silveira P; Horvath L; Clark G, 2019, 'Novel Targets for an In Vivo DC Anti-Prostate Cancer Vaccine', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, pp. 64 - 65, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000476915200065&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Papers | 2016
    Hwang SJE; Park J; Wakade D; Byth K; Chou S; Kong BY; Carlino MS; Fernandez-Penas P, 2016, 'Cutaneous toxicities of anti-programmed cell death1 antibodies combined with anti-cytotoxic T-lymphocyte-associated protein 4 use in metastatic melanoma patients', in AUSTRALASIAN JOURNAL OF DERMATOLOGY, WILEY-BLACKWELL, pp. 10 - 10, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000387333500026&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Papers | 2015
    Kong BY; Saunders CAB; Liniker E; Ramanujam S; Kefford RF; Guminski A; Menzies AM; Long GV; Carlino MS, 2015, 'FDG-PET METABOLIC ACTIVITY IN METASTATIC MELANOMA AFTER LONG-TERM TREATMENT WITH ANTI-PD-1 ANTIBODIES', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY-BLACKWELL, pp. 40 - 40, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000357957300003&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

2022/MRF2023943 - Supporting Australian Brain Cancer Research with an integrated network of platforms (Associate Investigator)

2021/MRF2015365 - LUMOS: Low and Anaplastic Grade Glioma Umbrella Study of Molecular Guided TherapieS (Associate Investigator)

 

 

Predictive factor in treatment sequencing for lung cancer brain metastases treated with immunotherapy

Radiomic biomarkers of response in brain metastases

Biomarkers of response to immunotherapy and precision medicine based approaches to lung cancer

Development of brain cancer clinical trials and translational research